What follow‑up schedule and tests (e.g., imaging, blood work) should I have to monitor for recurrence of Colorectal...

April 7, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Colorectal Cancer Follow-Up & Surveillance Schedule

I'll walk you through the standard surveillance recommendations based on your cancer stage. This is important because catching recurrence early—when it's still treatable—can make a real difference.

Key Principle: Why Surveillance Matters

According to NCCN Guidelines, about 80% of colorectal cancer recurrences happen in the first 3 years after surgery, and 95% occur within 5 years. The goal of surveillance is to:

  • Detect recurrence early enough for potentially curative treatment
  • Identify new polyps or cancers before they become advanced
  • Monitor for treatment side effects

STAGE-SPECIFIC SURVEILLANCE PLANS

STAGE I DISEASE (Lower recurrence risk)

Physical Exams:

  • Every 3-6 months for 2 years
  • Then every 6 months for a total of 5 years

Blood Work:

  • CEA (Carcinoembryonic Antigen) testing is NOT routinely recommended for stage I, unless your doctor believes you're a candidate for aggressive surgery if recurrence is found

Colonoscopy:

  • At 1 year after surgery
  • Then at 3 years, then every 5 years
  • Exception: If advanced adenoma (large polyp, villous polyp, or high-grade dysplasia) is found, repeat in 1 year

Imaging:

  • NOT routinely recommended for stage I disease (to avoid unnecessary radiation exposure and false alarms)

STAGE II & III DISEASE (Higher recurrence risk)

Physical Exams:

  • Every 3-6 months for 2 years
  • Then every 6 months for a total of 5 years

Blood Work - CEA Testing:

  • Every 3-6 months for 2 years
  • Then every 6 months for a total of 5 years
  • Note: CEA is only recommended if you're a potential candidate for surgery to remove recurrent disease

Imaging - CT Scans (Chest, Abdomen, Pelvis):

  • Every 6-12 months for 5 years (more frequent in first 2 years if high-risk stage II)
  • Purpose: Look for potentially resectable (removable) metastases in lungs and liver
  • NOT recommended beyond 5 years
  • PET/CT scans are NOT recommended for routine surveillance

Colonoscopy:

  • At 1 year after surgery
  • Then at 3 years, then every 5 years
  • Same advanced adenoma rules as stage I

STAGE IV DISEASE (After curative-intent surgery with no evidence of disease)

Physical Exams:

  • Every 3-6 months for 2 years
  • Then every 6 months for a total of 5 years

Blood Work - CEA:

  • Every 3-6 months for 2 years
  • Then every 6 months for a total of 5 years

Imaging - CT Scans (Chest, Abdomen, Pelvis):

  • Every 3-6 months for first 2 years (more frequent than earlier stages)
  • Then every 6-12 months for up to 5 years total
  • Purpose: Detect resectable recurrent disease early

Colonoscopy:

  • Same schedule as stages II-III

WHAT THESE TESTS ACTUALLY LOOK FOR

| Test | What It Detects | Frequency | |------|-----------------|-----------| | CEA Blood Test | Tumor marker that may rise if cancer recurs | Every 3-6 months (years 1-2), then every 6 months | | CT Scan | Metastases (spread) in lungs, liver, abdomen | Every 6-12 months (stage II/III); every 3-6 months (stage IV) | | Colonoscopy | New polyps or local recurrence in colon | 1 year post-surgery, then 3 years, then every 5 years | | Physical Exam | Signs of recurrence, side effects, new symptoms | Every 3-6 months (years 1-2), then every 6 months |


IMPORTANT CLARIFICATIONS

What's NOT recommended:

  • PET/CT scans for routine surveillance (not sensitive enough for early detection)
  • CEA monitoring beyond 5 years (benefit decreases)
  • CT scans beyond 5 years (routine surveillance)

Why the time limits? According to NCCN Guidelines, approximately 10% of patients recur after 3 years, but the benefit of intensive surveillance decreases significantly after 5 years. After that, imaging is typically done only if you have symptoms or signs of recurrence.


QUESTIONS TO ASK YOUR ONCOLOGIST

  1. What is my specific stage, and does that change any of these recommendations for me?

  2. Am I considered "high-risk" stage II (which might warrant more frequent imaging)?

  3. If my CEA starts rising, what's the plan? (This typically triggers additional imaging and possibly PET/CT)

  4. How long should I continue surveillance? (Standard is 5 years, but your doctor may recommend longer based on your individual risk)

  5. What symptoms should I report between visits? (Weight loss, abdominal pain, changes in bowel habits, blood in stool)

  6. Can we discuss the pros and cons of more vs. less intensive surveillance for my situation?

  7. What happens after 5 years—do I still need regular follow-up?


KEY SOURCES

According to the NCCN Guidelines for Colon Cancer (Version 5.2025), these recommendations balance the benefit of catching recurrence early against the harms of over-surveillance (radiation exposure, psychological stress, false alarms). The American Society of Clinical Oncology (ASCO) endorses similar guidelines through Cancer Care Ontario.


BOTTOM LINE

Your surveillance plan depends heavily on your stage. Stage I gets minimal surveillance; stages II-IV get progressively more intensive monitoring. The goal is catching recurrence when it's still treatable, but not creating unnecessary anxiety or radiation exposure. Your oncologist will personalize this based on your specific pathology and risk factors.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2